Target intelligence / Profile preview

Tumor necrosis factor receptor superfamily member 1B (TNFR2) (TNFR2)

Target
TNFR2
Molecular classification
Receptor, Tumor necrosis factor receptor superfamily
01

Overview

Tumor necrosis factor receptor superfamily member 1B (TNFR2) is a membrane-bound receptor that binds to tumor necrosis factor-alpha (TNF-alpha) with high affinity, mediating crucial signaling pathways involved in cell survival, immune regulation, and tissue regeneration. Unlike TNFR1, which is ubiquitously expressed and primarily drives pro-inflammatory and apoptotic pathways, TNFR2 expression is highly restricted to specific immune cell subsets, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), as well as certain endothelial and central nervous system cells. In the tumor microenvironment, TNFR2 is often aberrantly upregulated, promoting tumor cell proliferation, immune evasion, and drug resistance by enhancing the suppressive activity of Tregs. Consequently, TNFR2 has emerged as a highly promising therapeutic target in oncology and autoimmune diseases. Antagonistic antibodies, such as BI-1808, are being developed to deplete immunosuppressive Tregs and reprogram myeloid cells to enhance anti-tumor immunity, while selective TNFR2 agonists, such as TRB-061, are being investigated to expand Tregs and treat inflammatory conditions like atopic dermatitis and multiple sclerosis.

Other names
Tumor necrosis factor receptor superfamily member 1BTumor necrosis factor receptor 2TNF-R2Tumor necrosis factor receptor type IITNF-RIITNFR-IIp75p80 TNF-alpha receptorCD120bTNFRSF1BTNFBR
02

Mechanism of action

Drugs targeting TNFR2 act either as antagonists or agonists. Antagonistic antibodies block the binding of TNF-alpha to TNFR2 and engage Fcγ receptors to deplete immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, thereby enhancing anti-tumor immune responses. Conversely, agonistic antibodies selectively activate TNFR2 signaling to expand and enhance the suppressive function of Tregs, which helps to restore immune tolerance in autoimmune and inflammatory diseases.

03

Biological functions

Signal transductionImmune responseApoptosisCell proliferationCell survivalMyeloid cell differentiationT-regulatory cell expansion
04

Disease associations

CancerInflammationAutoimmune diseaseAtopic dermatitisMultiple sclerosisRheumatoid arthritisLymphoma
05

Safety considerations

Systemic immune activationAutoimmunity (with antagonists)Immunosuppression (with agonists)Cytokine release syndromeOn-target off-tumor toxicityResistance to Treg-mediated suppression
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

TNFR2 expressionTreg levels (CD4+CD25+FOXP3+TNFR2+)CD8+ T-cell infiltrationIL-10CCR8CD39-positive Tregs

Beyond the preview

Go deeper on Tumor necrosis factor receptor superfamily member 1B (TNFR2) (TNFR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 1B (TNFR2) (TNFR2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call